Leflunomide Tablet
Product Images NDC 72162-2410

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 72162-2410). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Cfa52b95 F6ee 4a2c A320 E190f716d33b 01)

Chemical structure diagram of leflunomide, showing its molecular arrangement with labeled functional groups including a trifluoromethyl-substituted phenyl ring and an isoxazole ring with associated atoms and bonds.*

FDA Label Image

. (Cfa52b95 F6ee 4a2c A320 E190f716d33b 02)

Chemical structure of teriflunomide, shown with labeled atoms and bonds representing its molecular composition.*

FDA Label Image

Image (Cfa52b95 F6ee 4a2c A320 E190f716d33b 03)

A bar chart displaying the percentage of ACR 20 responders at the endpoint of three clinical trials of varying durations (12 months, 6 months, and 12 months). It compares response rates for leflunomide (L), methotrexate (M), placebo (P), and sulfasalazine (S) across the trials, with response percentages indicated on the vertical axis from -20% to 70%.*

FDA Label Image

Image (Cfa52b95 F6ee 4a2c A320 E190f716d33b 04)

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders on the y-axis and months on the x-axis (0 to 12 months). It compares three treatments: PL, MTX, and LEF, with LEF represented by a solid triangle line, MTX by a dashed square line, and PL by a dotted circle line. The graph displays response trends over the 12-month period.*

FDA Label Image

. (Cfa52b95 F6ee 4a2c A320 E190f716d33b 05)

A bar chart titled 'Change in Sharp Score' comparing the progression of Sharp scores across three clinical trials over different durations (6 and 12 months). It shows data for leflunomide (L), methotrexate (M), sulfasalazine (S), and placebo (P). The Y-axis indicates the level of progression and regression, with values displayed above each bar.*

FDA Label Image

. (Cfa52b95 F6ee 4a2c A320 E190f716d33b 06)

Bar graph titled 'Change in Functional Ability Measure' showing improvement levels measured by the HAQ Disability Index across three trials over 6 to 12 months. It compares Leflunomide, Methotrexate, Placebo, and Sulfasalazine treatments with numerical change values indicated for each group in the trials.*

FDA Label Image

4b95cee-6630-482c-93a4-2a489f7c0c03 (Cfa52b95 F6ee 4a2c A320 E190f716d33b 07)

FDA Label Image

Label (Lbl721622410)

Leflunomide Tablets USP 20 mg label showing a package of 30 tablets. The label includes storage instructions, dosage information, manufacturer Heritage Pharma Labs Inc., and relabeler Bryant Ranch Prepack. The NDC is 72162-2410-3. The label also features QR codes for the package insert and prescribing information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.